Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("BIODISPONIBILITE PRINCIPE ACTIF")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 77

  • Page / 4
Export

Selection :

  • and

BIOLOGIC AVAILABILITY, DETERMINANT FACTOR OF THERAPEUTIC ACTIVITY OF DRUGS. STATEMENT OF THE PROBLEM AND PHYSIOLOGICAL CONSIDERATIONS = BIODISPONIBILITE, FACTEUR DETERMINANT DE L'ACTIVITE THERAPEUTIQUE DES MEDICAMENTS. ETAT DU PROBLEME ET CONSIDERATIONS PHYSIOLOGIQUESWAGNER JG.1973; DRUG INTELLIG. CLIN. PHARM.; U.S.A.; DA. 1973; VOL. 7; NO 4; PP. 168-176; BIBL. 14REF.Serial Issue

VERFUEGBARKEITSPRUEFUNG IN VITRO-ERFORDERNIS, MOEGLICHKEITEN, GRENZEN = RECHERCHE DE LA BIODISPONIBILITE IN VITRO. EXIGENCES, POSSIBILITES, LIMITESDIBBERN HW.1973; PHARM. INDUSTR.; DTSCH.; DA. 1973; VOL. 35; NO 2; PP. 76-78; ABS. ANGL.; BIBL. 50 REF.Serial Issue

PREDICTION OF SYSTEMIC AVAILABILITY FROM PLASMA-LEVEL DATA AFTER ORAL DRUG ADMINISTRATION = LA PREDICTION DE LA DISPONIBILITE GENERALE D'APRES LES DONNEES DU TAUX PLASMATIQUE APRES L'ADMINISTRATION PER OS DES MEDICAMENTSPERRIER D; GIBALDI M; BOYES RN et al.1973; J. PHARM. PHARMACOL.; G.B.; DA. 1973; VOL. 25; NO 3; PP. 256-257; BIBL. 7 REF.Serial Issue

BIOPHARMAZIE DER INJEKTABILIA. I. INJECTABILIA MIT SOFORTWIRKUNG = BIOPHARMACIE DES PRODUITS INJECTABLES. I. PRODUITS INJECTABLES AVEC UNE ACTION IMMEDIATE1973; PHARM. INDUSTR.; DTSCH.; DA. 1973; VOL. 35; NO 5; PP. 273-285; ABS. ANGL.; BIBL. 119REF.Serial Issue

BIOPHARMACEUTICAL STUDIES OF COMMERCIAL HYDROCHLOROTHIAZIDE FORMULATIONSMCGILVERAY IJ; HOSSIE RD; MATTOK GL et al.1973; CANAD. J. PHARM. SCI.; CANADA; DA. 1973; VOL. 8; NO 1; PP. 13-15; ABS. FR.; BIBL. 9 REF.Serial Issue

DISSOLUTION-DIALYSIS METHOD OF ASSESSING IN VITRO DRUG AVAILABILITY OF PREDNISOLONE TABLETS = METHODE DE DISSOLUTION ET DIALYSE POUR L'ESSAI IN VITRO DE LA DISPONIBILITE DE LA PREDNISOLONE EN COMPRIME DISPONIBILITENORTHERN RE; LACH JL; FINCHER JH et al.1973; AMER. J. HOSP. PHARM.; U.S.A.; DA. 1973; VOL. 30; NO 7; PP. 622-627; BIBL. 14REF.Serial Issue

BIOLOGISCHE VERFUEGBARKEIT. BESTIMMUNG UND BEURTEILUNG = BIODISPONIBILITE. DETERMINATION ET EVALUATIONRITSCHEL WA.1973; OESTERR. APOTHEKER ZTG; OESTERR.; DA. 1973; VOL. 27; NO 4; PP. 65-72; BIBL. 23REF.Serial Issue

THE AVAILABILITY OF ORALLY ADMINISTERED NORTRIPTYLINE = DISPONIBILITE PHYSIOLOGIQUE DE LA NORTRIPTYLINE ADMINISTREE PAR VOIE ORALEALEXANDERSON B; BORGA O; ALVAN G et al.1973; EUROP. J. CLIN. PHARMACOL.; GERM.; DA. 1973; VOL. 5; NO 3; PP. 181-185; BIBL. 14 REF.Serial Issue

USE OF CONFIDENCE INTERVALS IN ANALYSIS OF COMPARATIVE BIOAVAILABILITY TRIALS = L'EMPLOI DES INTERVALLES DE CONFIANCE DANS L'ANALYSE DES ESSAIS DE BIODISPONIBILITE COMPARES1972; J. PHARM. SCI.; U.S.A.; DA. 1972; VOL. 61; NO 8; PP. 1340-1341Serial Issue

BIOAVAILABILITY IN THE CLINICAL EVALUATION OF DRUGS1972; DRUG INTELLIG. CLIN. PHARM.; U.S.A.; DA. 1972; VOL. 6; NO 7; PP. 246-256; BIBL. 33 REF.Serial Issue

BIOPHARMACEUTICS AND PHARMACOKINETICSBENET LZ.1972; ANNU. REP. MEDICIN. CHEM.; U.S.A.; DA. 1972; VOL. 7; PP. 259-268; BIBL. 3P.Serial Issue

BIOAVAILABILITY OF POTASSIUM FROM A SLOW-RELEASE TABLET = LA BIODISPONIBILITE DU POTASSIUM A PARTIR DE COMPRIMES AVEC LIBERATION LENTEBEN ISHAY D; ENGELMAN K.1973; CLIN. PHARMACOL. THERAPEUT.; U.S.A.; DA. 1973; VOL. 14; NO 2; PP. 250-258; BIBL. 9REF.Serial Issue

BIOPHARMACEUTICAL EVALUATION OF CYANIDANOL TABLETS USING PHARMACOKINETIC TECHNIQUES = EVALUATION BIOPHARMACEUTIQUE DES COMPRIMES DE CYANIDANOL EN UTILISANT DES TECHNIQUES PHARMACOCINETIQUESGILES AR; GUMMA A.1973; ARZNEIMITTEL-FORSCH.; DTSCH.; DA. 1973; VOL. 23; NO 1; PP. 99-100; ABS. ALLEM.; BIBL. 9 REF.Serial Issue

BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE = DEMONSTRATION BIOLOGIQUE ET PHARMACOCINETIQUE DE L'EQUIVALENCE GENERIQUE DE 3 PREPARATIONS D'IMIPRAMINE: COMPARAISON AVEC UN NOUVEL ANALOGUE DE L'IMIPRAMINETUCK JR; KAHAN E; SIWERS B et al.1973; ACTA PHARMACOL. TOXICOL.; DANEM.; DA. 1973; VOL. 32; NO 3-4; PP. 304-313; BIBL. 1P.1/2Serial Issue

CALCULATION OF ABSORPTION RATE CONSTANTS FOR DRUGS WITH INCOMPLETE AVAILABILITY = CALCUL DES CONSTANTES DES VITESSES D'ABSORPTION POUR LES MEDICAMENTS AVEC UNE DISPONIBILITE INCOMPLETEPERRIER D; GIBALDI M.1973; J. PHARM. SCI.; U.S.A.; DA. 1973; VOL. 62; NO 2; PP. 225-228; BIBL. 10REF.Serial Issue

ROLE OF DRUG METABOLISM IN DRUG RESEARCH AND DEVELOPMENT: IMPORTANCE OF DRUG METABOLISM IN CLINICAL PHARMACOLOGICAL EVALUATION OF NEW DRUGSLEMBERGER L.1972; J. PHARM. SCI.; U.S.A.; DA. 1972; VOL. 61; NO 10; PP. 1690-1694; BIBL. 22REF.Serial Issue

BIOAVAILABILITY OF CODEINE PREPARATIONS IN THE RATBENEDETTI MS; LARUE DA.1973; ARZNEIMITTEL-FORSCH.; DTSCH.; DA. 1973; VOL. 23; NO 6; PP. 826-828; ABS. ALLEM.; BIBL. 9REF.Serial Issue

GI ABSORPTION OF TWO CRYSTAL FORMS OF SULFAMETER IN MAN = ABSORPTION GASTROINTESTINALE DE 2 FORMES CRISTALLINES DE SULFAMETER CHEZ L'HOMMEKHALIL SA; MOUSTAFA MA; EBIAN AR et al.1972; J. PHARM. SCI.; U.S.A.; DA. 1972; VOL. 61; NO 10; PP. 1615-1617; BIBL. 22 REF.Serial Issue

PHYSIOLOGICAL DISPOSITION OF FENOPROFEN IN MAN. III. METABOLISM AND PROTEIN BINDING OF FENOPROFEN = DISPONIBILITE PHYSIOLOGIQUE DU FENOPROFEN CHEZ L'HOMME. III. METABOLISME ET FIXATION PROTEIQUE DU FENOPROFENRUBIN A; WARRICK P; WOLEN RL et al.1972; J. PHARMACOL. EXPER. THERAPEUT.; U.S.A.; DA. 1972; VOL. 183; NO 2; PP. 449-457; BIBL. 14 REF.Serial Issue

CORTICOSTEROID OINTMENTS: COMPARISON BY TWO HUMAN BIOASSAYS = POMMADE AUX CORTICOSTEROIDES: COMPARAISON DE DEUX ESSAIS BIOLOGIQUES SUR L'HOMMEBURDICK KH; HALEBLIAN JK; POULSEN BJ et al.1973; CURR. THERAPEUT. RES.; U.S.A.; DA. 1973; VOL. 15; NO 5; PP. 233-242; BIBL. 12REF.Serial Issue

PHARMACOLOGIE CLINIQUE ET CONTROLE DES MEDICAMENTSFRIEBEL H.1973; CHRON. O.M.S.; SUISSE; DA. 1973; VOL. 27; NO 3; PP. 94-98; BIBL. 10 REF.Serial Issue

VARIATIONS IN THEOPHYLLINE, EPHEDRINE HYDROCHLORIDE AND PHENOBARBITAL TABLETS MANUFACTURED BY THIRTEEN FIRMSLACH JL; TING FONG CHIN; PARROTT EL et al.1972; AMER. J. HOSP. PHARM.; U.S.A.; DA. 1972; VOL. 29; NO 12; PP. 1043-1047; BIBL. 9 REF.Serial Issue

COMPARATIVE BIOAVAILABILITY OF THREE BRANDS OF AMPICILLIN1972; CANAD. MED. ASS. J.; CANADA; DA. 1972; VOL. 107; NO 3; PP. 203-209; ABS. FR.; BIBL. 20 REF.Serial Issue

ASPECTS BIOPHARMACEUTIQUES DES PREPARATIONS MEDICAMENTEUSE PAR VOIE RECTALENEUWALD F.1972; PHARMA INTERNATION.; ALLEM.; DA. 1972; NO 2; PP. 5-11 (6P.); BIBL. 11REF.Serial Issue

FAILURE OF USP TABLET DESINTEGRATION TEST TO PREDICT PERFORMANCE IN MAN = L'ECHEC DE L'ESSAI DE DESINTEGRATION DES COMPRIMES DE L'USP POUR PREDIRE LES PERFORMANCES CHEZ L'HOMMEWAGNER JG; WILKINSON PK; SEDMAN AJ et al.1973; J. PHARM. SCI.; U.S.A.; DA. 1973; VOL. 62; NO 5; PP. 859-860Serial Issue

  • Page / 4